骨形成タンパク質の世界市場 - 産業規模、シェア、動向、機会、予測：タイプ別、用途別、地域別、競合別（2018年～2028年）

世界の骨形成タンパク質の市場規模は、2022年に7億1,043万米ドルに達し、2028年までのCAGRは3.22%で、予測期間中に目覚ましい成長を遂げると予測されています。

骨形成タンパク質の世界市場は、骨の形成と修復に重要な役割を果たす成長因子群の市場を指します。これらのタンパク質は新しい骨組織の産生を刺激し、様々な医療用途、特に整形外科や歯科の処置に使用されます。

主要市場促進要因

人口の高齢化と整形外科疾患の増加

高齢化と整形外科疾患の増加により、世界の医療の状況は大きく変化しています。この人口動態の変化による主要な受益者のひとつが、世界の骨形成タンパク質（BMP）市場です。顕著な骨再生特性を持つ成長因子群であるBMP（骨形成タンパク質）は、高齢者の医療ニーズに対応するための革新的なソリューションに対する需要の高まりに後押しされ、整形外科手術や脊椎手術において不可欠なものとなっています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の骨形成タンパク質市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（遺伝子組換えヒト骨形成タンパク質（rhBMP）-2、遺伝子組換えヒト骨形成タンパク質（rhBMP）-7）
  • 用途別（脊椎固定、外傷、再建外科、口腔顎顔面）
  • 地域別
  • 企業別（2022年）
• 製品市場マップ
  • タイプ別
  • 用途別
  • 地域別

第6章 北米の骨形成タンパク市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の骨形成タンパク質市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • 国別
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋の骨形成タンパク質市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の骨形成タンパク質市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの骨形成タンパク質市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の開発
• 合併・買収
• 製品発売

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• 事業概要
• 製品提供
• 最近の開発
• 財務
• 主要人員
• SWOT分析
  • Johnson & Johnson
  • Ember Therapeutics Inc
  • Integra LifeSciences Holdings Corp
  • Medtronic PLC
  • Bio-Techne Corp
  • Merck KGaA
  • Pfizer Inc
  • Stryker Corp
  • Thermo Fisher Scientific Inc
  • Zimmer Biomet Holdings Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Bone Morphogenetic Protein Market has valued at USD 710.43 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 3.22% through 2028. The Global Bone Morphogenetic Protein Market refers to the market for a group of growth factors that play a crucial role in bone formation and repair. These proteins stimulate the production of new bone tissue and are used in various medical applications, particularly in orthopedic and dental procedures.

Key Market Drivers

Aging Population and Increasing Orthopedic Conditions

The global healthcare landscape is undergoing a significant transformation due to the aging population and the increasing prevalence of orthopedic conditions. One of the key beneficiaries of this demographic shift is the Global Bone Morphogenetic Protein (BMP) Market. BMPs, a group of growth factors with remarkable bone-regenerating properties, have become indispensable in orthopedic and spinal surgeries, driven by the growing demand for innovative solutions to address the healthcare needs of older adults.

The aging population is a global phenomenon. According to the World Health Organization (WHO), the world's population over 60 years old is expected to nearly double by 2050, reaching around 2.1 billion. This demographic shift is primarily attributed to increased life expectancy and decreased birth rates, resulting in a higher proportion of elderly individuals.

As people age, the risk of orthopedic conditions and related disorders significantly increases. These conditions include osteoarthritis, osteoporosis, fractures, and degenerative disc diseases. The bones and joints naturally undergo wear and tear, making elderly individuals more susceptible to musculoskeletal problems.

BMPs are commonly used in spinal fusion surgeries, a procedure that stabilizes the spine by fusing two or more vertebrae together. As the aging population is more prone to spinal issues such as herniated discs and spinal stenosis, the demand for spinal fusion procedures utilizing BMPs is expected to surge. Aging individuals often experience more fractures due to weakened bones. BMPs can be employed to expedite the healing of fractures, allowing patients to regain mobility and independence more quickly. Hip and knee replacements are common among the elderly. BMPs enhance the integration of these implants with the patient's natural bone, ensuring longevity and improved post-surgical mobility.

The rising number of elderly patients with orthopedic conditions directly translates into a larger pool of potential BMP recipients. This expanded patient base is driving market growth. As the elderly population continues to grow, the demand for orthopedic surgeries and spinal procedures is expected to increase. BMPs are a critical component of these surgical interventions, further boosting market growth. The benefits of BMPs are not limited to orthopedics alone. These growth factors are increasingly being used in other areas, such as dental and craniofacial surgeries, further diversifying the BMP market. The aging population's unique healthcare needs have prompted increased research and development efforts in the BMP sector. These endeavors aim to improve the efficacy, safety, and versatility of BMP products.

Minimally Invasive Surgery

The realm of healthcare and surgery is witnessing a paradigm shift, with minimally invasive procedures emerging as a game-changer. These innovative surgical techniques not only benefit patients through reduced pain and faster recovery but also have a profound impact on the medical industry.

Patients undergoing minimally invasive procedures typically experience reduced pain and discomfort, leading to quicker post-operative recovery. Many MIS patients can be discharged sooner, which not only lowers healthcare costs but also frees up hospital resources for more patients. Smaller incisions result in minimal scarring, improving cosmetic outcomes and boosting patient satisfaction. Smaller incisions reduce the risk of post-operative infections, enhancing patient safety. Minimally invasive techniques often lead to reduced blood loss during surgery. Advanced imaging and robotic-assisted technologies used in MIS provide surgeons with enhanced precision and control.

In minimally invasive orthopedic surgeries, where smaller incisions are made, BMPs are utilized to promote bone healing and fusion. These growth factors significantly reduce the healing time, allowing patients to regain mobility and function more quickly. In traditional open surgeries, grafts are often required to support bone fusion. However, BMPs can minimize the need for these grafts, further reducing patient discomfort and surgical complications in minimally invasive procedures. BMPs have been shown to enhance fusion rates in spinal surgeries, particularly in minimally invasive spinal fusion procedures. Improved fusion outcomes contribute to long-term patient satisfaction and reduced healthcare costs. The minimally invasive approach, with the assistance of BMPs, allows surgeons to address a wider range of orthopedic and spinal conditions, from degenerative disc diseases to spinal instability. This expanded applicability is driving the adoption of BMPs in minimally invasive surgery.

The increasing acceptance of minimally invasive procedures by both patients and healthcare providers is resulting in a higher volume of surgeries. As BMPs are integral to many of these procedures, the BMP market is poised for substantial growth. Patients increasingly seek minimally invasive options due to the reduced pain and faster recovery they offer. As patient awareness and demand grow, healthcare facilities are likely to incorporate BMPs into their offerings to remain competitive. Ongoing advancements in surgical technologies, including those used in minimally invasive surgery, are expected to further enhance the efficiency and effectiveness of BMPs in bone healing. As BMPs continue to prove their worth in minimally invasive orthopedic and spinal surgeries, their application is diversifying into other fields, such as oral and maxillofacial surgery, further expanding the market's reach.

Advancements in Orthopedics

The field of orthopedics, dedicated to the diagnosis and treatment of musculoskeletal disorders, has been evolving rapidly over the years. One of the key drivers of this transformation is the continuous stream of advancements in orthopedic technologies and techniques. As these innovations unfold, they are not only improving patient outcomes but also significantly contributing to the growth of the Global Bone Morphogenetic Protein (BMP) Market.

The development of new materials, such as bioactive ceramics and advanced metals, has led to orthopedic implants that are more durable, biocompatible, and closer in properties to natural bone. These materials are often enhanced with BMPs to improve integration with the patient's bone. In addition, minimally invasive procedures are on the rise. Advanced imaging, robotic-assisted surgery, and specialized instruments are making it possible to perform complex orthopedic surgeries through smaller incisions. This trend is particularly relevant to the BMP market as it enhances the appeal of BMPs in minimally invasive surgeries. 3D printing and computer-assisted design and manufacturing have made it possible to create patient-specific orthopedic implants. These custom-made implants improve fit and function, and the use of BMPs can enhance the integration of these implants. Orthobiologics, including BMPs, are being integrated into orthopedic treatments to stimulate natural healing and regeneration. This is particularly relevant in cases of cartilage repair, osteoarthritis management, and non-union bone fractures. The use of data analytics and artificial intelligence is improving patient assessment, treatment planning, and post-operative care in orthopedics. This enhances the precision and effectiveness of orthopedic procedures, including those involving BMPs.

As orthopedic implant materials become more advanced, BMPs are utilized to improve the integration of these materials with the patient's bone. This not only enhances implant durability but also reduces the chances of complications. In spinal fusion surgeries, where orthopedic advancements are frequent, BMPs have been instrumental in improving fusion rates. This is crucial in the treatment of spinal conditions, which are common among aging individuals. The focus on biological enhancements in orthopedics aligns well with BMPs, which are known for their regenerative properties. In cases of cartilage repair and osteoarthritis, BMPs can stimulate the body's natural healing processes.

As orthopedic advancements become standard practice, the use of BMPs is expected to grow, particularly in spinal and orthopedic surgeries where their regenerative potential is most critical. Patients benefit from improved orthopedic procedures that incorporate BMPs, experiencing less pain, faster recovery, and better long-term outcomes. This patient satisfaction fosters the growth of the BMP market. The continuous evolution of orthopedic technologies and techniques creates opportunities for further research and development in BMP products, ensuring they remain at the forefront of innovation. The diversification of orthopedic advancements into new subspecialties, such as sports medicine and joint preservation, opens doors for BMPs to be applied in a wider range of conditions, expanding the BMP market's reach.

Strong Market Players

The Global Bone Morphogenetic Protein (BMP) Market is undergoing a phase of rapid expansion, and one of the key drivers behind this growth is the active participation and innovation of strong market players. Companies in the healthcare and biotechnology sectors are continually pushing the boundaries of research and development, which not only enhances the BMP market but also brings about significant advancements in orthopedic and regenerative medicine.

Strong market players allocate substantial resources to research and development, leading to the innovation of new BMP products, delivery methods, and applications. This commitment to advancing BMP technology keeps the market at the forefront of scientific progress. These companies often initiate and sponsor clinical trials to evaluate the safety and efficacy of BMP products in a variety of medical applications. This research provides valuable data that supports the expanded use of BMPs, enhancing the credibility of the BMP market. Experienced market players are well-versed in navigating complex regulatory landscapes. Their expertise in gaining regulatory approvals for BMP products not only ensures product safety but also opens doors for market expansion. Leading companies have established extensive distribution networks that enable them to reach healthcare providers and facilities worldwide. This broad reach facilitates the adoption of BMP products in various regions, contributing to the global market's growth. These market players often engage in strategic collaborations and acquisitions to expand their BMP product portfolios. This enables them to offer a wider range of BMP solutions, catering to diverse medical needs. Leading companies are active in educating healthcare professionals about the benefits and applications of BMPs. Their educational initiatives help increase awareness and drive the adoption of BMPs in clinical practice.

The ongoing innovation and competition among market players lead to the development of more advanced BMP products. This stimulates demand for BMPs as healthcare providers seek the most effective and cutting-edge solutions for their patients. The active participation of these market leaders ensures that BMPs are applied in a broader range of medical disciplines. As BMPs find new applications in fields like dentistry, oral and maxillofacial surgery, and craniofacial reconstruction, the BMP market expands accordingly. Strong market players are committed to maintaining high-quality standards for BMP products. Their stringent quality control processes build trust in the reliability and safety of BMPs, encouraging their adoption by healthcare professionals. The global distribution networks of these companies enable BMP products to reach a wide range of healthcare facilities and providers, both in developed and emerging markets. This accessibility fosters the BMP market's growth on a global scale.

Key Market Challenges

Safety Concerns

One of the primary challenges confronting the BMP market is the safety concerns associated with these growth factors. Some studies have raised questions about potential side effects and complications, such as excessive bone growth, inflammation, or complications associated with BMP products. As a result, healthcare providers and regulatory agencies are taking a closer look at the safety profile of BMPs, necessitating rigorous clinical evaluation and ongoing monitoring to ensure patient safety.

Alternative Bone Graft Materials

The availability of alternative bone graft materials, such as synthetic grafts and allografts, poses a challenge to the BMP market. Surgeons and healthcare providers may opt for these alternatives due to concerns about BMP safety or cost considerations. The BMP market must continuously demonstrate the unique advantages of BMPs over other options.

Long-Term Efficacy

Ensuring the long-term efficacy and safety of BMPs remains a challenge. Some studies suggest that the bone formed with BMPs may be less dense and less mechanically stable than natural bone. Long-term follow-up studies are needed to address these concerns and provide evidence of BMPs' lasting benefits.

Key Market Trends

Regenerative Medicine Integration

The integration of BMPs into the field of regenerative medicine is a prominent trend. BMPs have been utilized for bone regeneration, but their applications are expanding into soft tissue and cartilage repair. This trend will foster collaborations between orthopedic and regenerative medicine specialists, opening new avenues for BMP research and applications.

Advanced Delivery Systems

Advancements in delivery systems for BMPs are on the horizon. These systems will enable precise and controlled release of BMPs at the site of treatment. Enhanced delivery methods will improve the safety and effectiveness of BMPs, reducing potential side effects and complications.

3D Printing and Implant Customization

The use of 3D printing in orthopedics is revolutionizing implant design. Customized, patient-specific implants are becoming more common, and BMPs are playing a vital role in ensuring these implants integrate seamlessly with the patient's natural bone. This trend enhances implant longevity and overall patient satisfaction.

Segmental Insights

Application Insights

Based on the category of Application, it is anticipated that spinal fusion will capture a significant portion of the market. Spinal fusion involves the utilization of bone morphogenetic protein (BMP), a protein known for its capacity to stimulate bone formation in the human body. BMP finds extensive use in spinal fusion procedures. Research indicates that BMP is widely embraced due to its ability to promote fusion at a rate surpassing that of conventional bone graft surgery. This attribute provides surgeons with the advantage of enhanced fusion rates, obviating the complexities associated with harvesting iliac crest autografts (hip grafts). Avoiding the use of hip grafts reduces surgical duration and lowers complication rates, resulting in swifter and less painful recovery periods. The upswing in spinal surgeries, coupled with the facilitative role of BMP, is driving the rapid expansion of its application in spinal fusion procedures.

Additionally, a study published in the National Library of Medicine in May 2022 reveals that annually, between 250,000 and 500,000 individuals worldwide suffer from spinal cord injuries, with the majority stemming from preventable causes like violence and car accidents. In the United States, around 17,000 new cases of spinal cord injuries are reported each year, and an estimated 282,000 people live with such injuries. Notably, men predominate among patients with sports-related spinal cord injuries, with the age group of 16 to 30 years being at the highest risk for such injuries. Consequently, the high incidence of spinal cord injuries is driving demand for spinal fusion devices in the forthcoming years. Furthermore, the growing preference for minimally invasive surgical techniques, owing to their numerous advantages, is fueling the overall market expansion.

Type Insights

The rhBMP-2, or recombinant human Bone Morphogenetic Protein-2, is poised to experience substantial market dominance during the forecast period in the Global Bone Morphogenetic Protein Market for several compelling reasons. First and foremost, rhBMP-2 has demonstrated remarkable efficacy in stimulating bone formation, making it an indispensable component of spinal fusion surgeries, where it facilitates fusion rates superior to traditional bone graft procedures. Its ability to expedite the healing process and reduce complications associated with autograft harvesting, particularly from the iliac crest, contributes to its growing popularity. Additionally, rhBMP-2 addresses a pressing global healthcare issue, as an increasing number of individuals suffer from spinal cord injuries each year. As the demand for spinal fusion devices surges, driven by both injury cases and a preference for minimally invasive techniques, rhBMP-2 is well-positioned to capture a significant market share, reflecting its pivotal role in enhancing patient outcomes and improving surgical procedures in this evolving market landscape.

Regional Insights

n the Bone Morphogenetic Protein Market, North America is poised to claim a substantial market share throughout the forecast period. This region has been experiencing significant growth and is expected to maintain its dominant position in the market, primarily due to its well-established healthcare system and the widespread adoption of cutting-edge technologies. An article published in the National Library of Medicine in August 2020 highlights the approval of the protein molecule known as rhBMP-2 by the United States Food and Drug Administration, which has emerged as a preferred choice for bone-related surgeries in the United States. In line with this, the American Association of Neurological Surgeons reported in 2021 that approximately 450,000 individuals in the United States were living with spinal cord injuries, underscoring the high demand for effective solutions in this region. Furthermore, with back pain affecting 80% of Americans at some point in their lives, as indicated in a January 2022 article titled "40 Back Pain Statistics," there exists significant potential for the utilization of bone morphogenetic proteins in the country. Notably, traumatic incidents, falls, accidents, and road traffic collisions contribute to spinal injuries, with data from the "Ministry of Communications and Transportation (Mexico)" updated in September 2020 revealing that 8,500 individuals were injured in road traffic accidents in the region.

Key Market Players

Johnson & Johnson

Ember Therapeutics Inc

Integra LifeSciences Holdings Corp

Medtronic PLC

Bio-Techne Corp

Merck KGaA

Pfizer Inc

Stryker Corp

Thermo Fisher Scientific Inc

Zimmer Biomet Holdings Inc

Report Scope:

In this report, the Global Bone Morphogenetic Protein Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bone Morphogenetic Protein Market, By Type:

• Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
• Recombinant Human Bone Morphogenetic Protein (rhBMP) -7

Bone Morphogenetic Protein Market, By Application:

• Spinal Fusion
• Trauma
• Reconstructive Surgery
• Oral-maxillofacial

Bone Morphogenetic Protein Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Bone Morphogenetic Protein Market.

Available Customizations:

• Global Bone Morphogenetic Protein market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bone Morphogenetic Protein Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7)
  • 5.2.2. By Application (Spinal Fusion, Trauma, Reconstructive Surgery, Oral-maxillofacial)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Type
  • 5.3.2. By Application
  • 5.3.3. By Region

6. North America Bone Morphogenetic Protein Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7)
  • 6.2.2. By Application (Spinal Fusion, Trauma, Reconstructive Surgery, Oral-maxillofacial)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bone Morphogenetic Protein Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Bone Morphogenetic Protein Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Bone Morphogenetic Protein Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Bone Morphogenetic Protein Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7)
  • 7.2.2. By Application (Spinal Fusion, Trauma, Reconstructive Surgery, Oral-maxillofacial)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bone Morphogenetic Protein Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Bone Morphogenetic Protein Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. France Bone Morphogenetic Protein Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Bone Morphogenetic Protein Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Bone Morphogenetic Protein Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Bone Morphogenetic Protein Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7)
  • 8.2.2. By Application (Spinal Fusion, Trauma, Reconstructive Surgery, Oral-maxillofacial)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Bone Morphogenetic Protein Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Japan Bone Morphogenetic Protein Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. India Bone Morphogenetic Protein Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. Australia Bone Morphogenetic Protein Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. South Korea Bone Morphogenetic Protein Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. South America Bone Morphogenetic Protein Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7)
  • 9.2.2. By Application (Spinal Fusion, Trauma, Reconstructive Surgery, Oral-maxillofacial)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bone Morphogenetic Protein Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Bone Morphogenetic Protein Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Bone Morphogenetic Protein Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Bone Morphogenetic Protein Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7)
  • 10.2.2. By Application (Spinal Fusion, Trauma, Reconstructive Surgery, Oral-maxillofacial)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bone Morphogenetic Protein Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Bone Morphogenetic Protein Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Bone Morphogenetic Protein Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
  • 10.3.4. Kuwait Bone Morphogenetic Protein Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Type
      • 10.3.4.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Johnson & Johnson
  • 14.6.2. Ember Therapeutics Inc
  • 14.6.3. Integra LifeSciences Holdings Corp
  • 14.6.4. Medtronic PLC
  • 14.6.5. Bio-Techne Corp
  • 14.6.6. Merck KGaA
  • 14.6.7. Pfizer Inc
  • 14.6.8. Stryker Corp
  • 14.6.9. Thermo Fisher Scientific Inc
  • 14.6.10. Zimmer Biomet Holdings Inc

15. Strategic Recommendations

16. About Us & Disclaimer